XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVENUE (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in Millions2022202120222021
Net product sales$10,813 $11,243 $33,606 $33,446 
Alliance revenues173 194 560 495 
Other revenues232 187 587 459 
Total Revenues$11,218 $11,624 $34,753 $34,400 
Revenue Recognition Gross-To-Net Adjustments
The following table summarizes GTN adjustments:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in Millions2022202120222021
Gross product sales$17,606 $17,335 $51,555 $49,676 
GTN adjustments(a)
Charge-backs and cash discounts(1,907)(1,908)(5,420)(5,214)
Medicaid and Medicare rebates(3,295)(2,625)(8,003)(6,482)
Other rebates, returns, discounts and adjustments(1,591)(1,559)(4,526)(4,534)
Total GTN adjustments(6,793)(6,092)(17,949)(16,230)
Net product sales$10,813 $11,243 $33,606 $33,446 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $10 million and $207 million for the three and nine months ended September 30, 2022, and $10 million and $282 million for the three and nine months ended September 30, 2021, respectively.
Revenue from External Customers by Products and Services
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in Millions2022202120222021
In-Line Products
Eliquis$2,655 $2,413 9,101 8,091 
Opdivo2,047 1,905 6,033 5,535 
Pomalyst/Imnovid886 851 2,620 2,478 
Orencia883 870 2,551 2,442 
Sprycel560 551 1,587 1,562 
Yervoy523 515 1,563 1,481 
Empliciti73 82 225 253 
Mature and other products441 480 1,338 1,459 
Total In-Line Products 8,068 7,667 25,018 23,301 
New Product Portfolio
Reblozyl190 160 518 400 
Abecma107 71 263 95 
Zeposia69 40 171 86 
Breyanzi44 30 127 47 
Inrebic21 22 62 54 
Onureg32 21 87 48 
Opdualag84 — 148 — 
Camzyos5 — 8 — 
Sotyktu1 — 1 — 
Total New Product Portfolio553 344 1,385 730 
Total In-Line Products and New Product Portfolio8,621 8,011 26,403 24,031 
Recent LOE Products(a)
Revlimid2,420 3,347 7,718 9,493 
Abraxane177 266 632 876 
Total Recent LOE Products2,597 3,613 8,350 10,369 
Total Revenues$11,218 $11,624 $34,753 $34,400 
United States$7,941 $7,296 $23,903 $21,694 
International3,062 4,052 10,216 12,075 
Other(b)
215 276 634 631 
Total Revenues$11,218 $11,624 $34,753 $34,400 
(a)    Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.
(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.